Nuvalent, Inc. announced plans to share preliminary data from the dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial for NVL-655, a novel ALK-selective inhibitor, in the second half of 2023, and reported ...
A priori enrollment goals were not established given the exploratory nature of this study. Primary analyses examined whether attitudes and the importance of clinical follow-up differed between genetic specialists and nongenetic specialists or by the type of finding (i.e., pathogenic variant in an ...
aPlease use this space to explain any time that has elapsed between your high school graduation and your anticipated enrollment at Penn State. Please provide a summary of why that gap occurred. If you attended another college or university during that time, please note it below and ensure that...
Phase 2 Initiation. Adverum is beginning preparations for the Phase 2 trial of ADVM-022 in wet AMD, with the intention of dosing the first patient in Q32022. Early feedback from potential Phase 2 investigators suggests completion of trial enrollment by year end ...
) or health savings account (HSA).The survey indicates that enrollment in consumer-directed plans will grow to 478,000 this year,up from 169,000 in 2003.About one-third of large companies expect to offer consumer...
Initially, the Kaiser Family Foundation projected the number of people who would lose coverage after the “disenrollment” process began following the end of COVID. Because state demographics varied widely,KFF estimated between 8% and 28%would lose coverage. In Montana, KFF estimated that would tr...
we’ll be doing mini previews at the beginning of each month — let us know if there are other things we should be looking forward to. (If you are a big fan of our bi-annual Previews and find yourself referring to them year-round,please consider supporting our efforts by becoming a me...
Using two-year panel data from the Medical Expenditure Panel Survey (MEPS) for 2004 to 2012, we examine how the intra-family allocation of health care spending responds to realized and anticipated changes in family economic status. We focus on the share of total family health care spending allo...
enrollment and continuation of its clinical studies or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that ...
(episodes lasting more than 7 days and less than 1 year) in the past 6 months, and the beta-1 389 arginine homozygous genotype that ARCA believes responds most favorably to Gencaro. The primary endpoint of the study is time to first...